Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates solid financial performance with projected revenue growth across segments, margin expansion, and double-digit EPS growth. The Q&A section reveals positive sentiment towards strategic initiatives like the CRUSH initiative, LaunchPad, and Labcorp OnDemand. Despite some uncertainties, such as reimbursement for esoteric tests, the overall outlook remains optimistic. The strong book-to-bill ratio and robust deal pipeline further support a positive sentiment. Without market cap data, the prediction leans towards a 'Positive' outlook, expecting a 2% to 8% stock price increase over the next two weeks.
Key Financial Performance
Enterprise Revenue $3.5 billion, up 5.8% year-over-year. Growth driven by 3.1% organic growth, 1.4% growth from net acquisitions, and 1.3% from foreign currency translation.
Enterprise Adjusted Operating Margin 14.4%, expanded by more than 30 basis points year-over-year. Increase primarily driven by organic revenue growth.
Adjusted Earnings Per Share (EPS) $4.25, up 10.6% year-over-year. Growth attributed to higher cash earnings and operational improvements.
Free Cash Flow $71 million, compared to a use of $108 million last year. Increase primarily due to higher cash earnings.
Diagnostics Revenue $2.8 billion, up 5% year-over-year. Growth includes 2.9% organic growth, 2% acquisition-driven growth, and 0.2% from foreign currency translation. Volume growth was 2.5%, constrained by adverse weather.
Diagnostics Adjusted Operating Income $459 million, 16.6% of segment revenue, up from $428 million or 16.3% last year. Margin expanded by 30 basis points, driven by organic growth despite adverse weather impact.
Biopharma Laboratory Services (BLS) Revenue $781 million, up 8.2% year-over-year. Growth includes 5.5% benefit from foreign currency translation and 3.7% organic growth, partially offset by Early Development strategic actions.
BLS Adjusted Operating Income $121 million, 15.5% of revenue, up from $107 million or 14.8% last year. Margin expanded by 60 basis points, driven by growth in Central Labs.
BLS Backlog $8.6 billion, with approximately $2.7 billion expected to convert into revenue over the next 12 months.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Specialty Testing: Labcorp is focusing on oncology, women's health, neurology, and autoimmune disease. Neurology experienced double-digit growth driven by Alzheimer's testing. Oncology also achieved double-digit growth supported by liquid biopsy tests and expanded access to MRD solutions.
Consumer Health: Labcorp OnDemand launched new tests for insulin resistance and pancreatic function. Customizable men's and women's health tests were introduced. A new mobile app, MyLabcorp, will launch in May, offering personalized test results and AI assistance for scheduling and payments.
New Diagnostic Tests: Labcorp launched the Labcorp Fentanyl Urine Visual Test, an FDA-cleared rapid screening test for fentanyl exposure, delivering results in 10 minutes.
Strategic Collaborations: Labcorp announced a nationwide collaboration with Children's Hospital of Philadelphia to expand pediatric diagnostics. Collaborated with Illumina to broaden access to genomic testing in oncology and launched a companion diagnostic for ovarian cancer patients.
Acquisitions: Completed acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement to manage their inpatient labs. Acquisition of outreach laboratory services from Parkview Health is on track.
AI and Robotics: Expanded collaboration with PathAI for digital pathology, partnered with Amazon Web Services and Datavant for an AI-powered Alzheimer's research platform, and collaborated with Optum.ai to streamline lab operations and enhance patient/provider experience.
Financial Performance: Revenue reached $3.5 billion, up 6%. Adjusted operating margin expanded by 30 basis points to 14.4%. Adjusted EPS grew 10.6% to $4.25. Free cash flow was $71 million.
Growth Strategy: Labcorp is focusing on partnerships with health systems and regional labs to expand patient/provider networks and drive volume growth. Specialty testing areas are expected to grow 2-3x faster than the broader diagnostics market.
Innovation and Ethics: Recognized by Fortune as one of the most innovative companies for the fourth year and by Ethisphere as one of the World's Most Ethical Companies in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Adverse Weather Impact: Adverse weather conditions constrained organic volume growth in the Diagnostics segment, reducing potential growth by approximately 1%.
Early Development Strategic Actions: Strategic actions in the Early Development segment led to a 1% reduction in organic growth for Biopharma Laboratory Services, impacting revenue generation.
Foreign Exchange Rates: Revenue growth was influenced by foreign currency translation, which could pose risks if exchange rates fluctuate unfavorably in the future.
Debt and Financial Obligations: The company has a significant debt position of $6.3 billion, which includes a $750 million term loan and upcoming retirement of $500 million senior notes. This could impact financial flexibility.
Operational Efficiency in Early Development: Efforts to streamline operations in the Early Development segment are ongoing and may pose risks if not completed successfully by the end of the second quarter.
Volume Growth Constraints: Organic volume growth in Diagnostics was limited to 1.1%, with adverse weather and other factors contributing to the constraint.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Revenue Growth: Enterprise revenue is expected to grow 5% to 6.1%, with a tailwind from foreign currency translation of approximately 40 basis points. Diagnostics segment revenue is projected to grow 5.1% to 5.9%, primarily driven by organic growth. Biopharma Laboratory Services (BLS) segment revenue is expected to grow 3.8% to 5.4%, with Central Labs revenue growing mid-single digits and Early Development revenue remaining relatively flat.
Adjusted EPS Guidance: The adjusted EPS guidance range is $17.70 to $18.35, with an implied growth rate at the midpoint of approximately 10%. The midpoint of the EPS range has been raised by $0.13 compared to prior guidance.
Free Cash Flow and Capital Expenditures: Free cash flow guidance remains $1.24 billion to $1.36 billion, weighted towards the second half of the year. Capital expenditures are expected to be approximately 4% of revenue, including investments in a new strategic facility to support long-term growth in Central Labs Services operations.
Margin Expansion: Enterprise margin expansion is expected, with improvements in both Diagnostics and BLS segments. BLS margin is projected to expand more than Diagnostics, driven by strong top-line growth in Central Labs and operating efficiencies in Early Development.
Book-to-Bill Ratio and Backlog: The BLS segment ended the quarter with a backlog of $8.6 billion, with approximately $2.7 billion expected to convert into revenue over the next 12 months. The trailing 12-month book-to-bill ratio remains healthy at 1.04.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid: $61 million in dividends were returned to shareholders in Q1 2026.
Share repurchases: $98 million worth of shares were repurchased in Q1 2026.
Share repurchase authorization: $700 million share repurchase authorization remains outstanding.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the impact of weather in the first quarter and thoughts around the ACA exchange and potential changes?
A:Weather had about a $15 million impact in the first quarter, primarily affecting the Diagnostics business. Organic volume growth would have been approximately 2% without the weather impact. Regarding the ACA exchange, the estimated 30 basis point impact on diagnostic volume remains valid, though the first quarter impact was immaterial. Enrollment is slightly better than expected, but it's too early to draw firm conclusions.
Q:What does the CRUSH initiative mean for Labcorp and the lab industry?
A:The CRUSH initiative aims to reduce fraud, waste, and abuse in the healthcare system. Labcorp supports the initiative but emphasizes the need to avoid unintended consequences, such as impeding Medicare patient access to necessary testing or punishing legitimate providers. Labcorp has submitted comments to CMS advocating for thoughtful implementation.
Q:What are the moving pieces around the trajectory of Diagnostics volume and mix dynamics?
A:Diagnostics revenue increased by 5% to $2.8 billion, with 3% organic growth and 2% from acquisitions. Volume growth was 2.5%, with 1.5% organic growth (which would have been 2% without weather impact) and 1.4% acquisition-driven. Specialty areas like neurology, oncology, and autoimmune disease are driving growth, with higher test prices and margins. The updated full-year Diagnostics revenue guidance midpoint is 5.5% growth.
Q:Can you provide more details on bookings trends in BLS and the quarterly book-to-bill ratio?
A:BLS grew 8% year-over-year, with 4% organic growth. Central Labs drove growth with an 11% increase (5% organic constant currency). Early Development was flat but progressing strategically. The quarterly book-to-bill ratio was 0.94, expected to grow sequentially in Q2 due to timing and strong RFPs. The trailing 12-month book-to-bill is 1.04, and Labcorp expects it to remain above 1 for the year.
Q:Can you elaborate on esoteric testing, including MRD and Alzheimer's testing?
A:Labcorp focuses on neurology, oncology, autoimmune disease, and women's health. Neurology, particularly Alzheimer's testing, is growing rapidly. Oncology tests, including liquid biopsies and tissue tests, are advancing, though reimbursement is not yet optimal. Success in specialty tests often leads to additional testing opportunities for related patient needs.
Q:What are your thoughts on the PAMA survey and the RESULTS Act?
A:Labcorp supports the RESULTS Act as a long-term solution and is advocating for its implementation. The impact of PAMA depends on the number of laboratories reporting data. Labcorp is encouraging broader participation to mitigate potential impacts. The RESULTS Act is awaiting a CBO score and CMS technical assistance.
Q:What is the outlook for consumer testing and Labcorp OnDemand?
A:Labcorp OnDemand is growing in double digits, offering over 200 biomarkers in various categories. Labcorp is investing in new products and targeted advertising. While focusing on high-margin specialty areas, Labcorp is cautious about competing in lower-margin consumer segments. The company sees significant growth opportunities in specialty areas and hospital partnerships.
Q:Can you provide an update on the LaunchPad initiative and margin progression?
A:LaunchPad is progressing well, leveraging technology like AI and robotics to reduce costs and improve customer experience. Diagnostics margins improved by 30 basis points in Q1, and BLS margins improved by 60 basis points. Full-year margin expansion is expected across both segments, contributing to double-digit EPS growth guidance.
Q:What are your assumptions regarding inflation, fuel costs, and weather impacts?
A:Fuel cost impact is estimated at $5-10 million for the year, mitigated by a shift to hybrid vehicles. Weather impacts are not explicitly forecasted but could influence the Diagnostics revenue guidance range of 5.1%-5.9% growth. Approximately 20%-25% of weather-affected appointments are recaptured through service centers.
Q:What is the current state of the deal pipeline for acquisitions and partnerships?
A:The deal pipeline remains strong, with health systems under financial stress driving partnership opportunities. Labcorp expects continued deal activity, particularly if PAMA is implemented, which could increase pressure on regional and hospital laboratories.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the reimbursement pathway for esoteric tests like MRD and Alzheimer's, stating that reimbursement is not yet optimal but may improve over time. Additionally, they did not provide clear insights into the number of laboratories expected to report data for the PAMA survey, which is critical for assessing its impact.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BLS segment
Central Labs
Crouse Health
Development enterprise
Dewey
Diagnostics Central
Early Development
Labcorp specialty
MyLabcorp
Senior Vice
acquisition capital
action Early
capital deployment
capital share
collaboration
deployment acquisition
diagnostics
drug
finance
flow capital
flow cash
function
health test
measure today
midpoint enterprise
need Labcorp
pathology
patient provider
platform
progress priority
release presentation
research
role
specialty area
tailwind currency
test result
track
use cash
webcast
world
LH Transcript
Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary indicates solid financial performance with projected revenue growth across segments, margin expansion, and double-digit EPS growth. The Q&A section reveals positive sentiment towards strategic initiatives like the CRUSH initiative, LaunchPad, and Labcorp OnDemand. Despite some uncertainties, such as reimbursement for esoteric tests, the overall outlook remains optimistic. The strong book-to-bill ratio and robust deal pipeline further support a positive sentiment. Without market cap data, the prediction leans towards a 'Positive' outlook, expecting a 2% to 8% stock price increase over the next two weeks.
Labcorp Holdings Inc. (LH) Q4 2025 Earnings Call Transcript
Unknown2-17
The earnings call reveals mixed sentiments. While revenue growth and EPS guidance are positive, there are concerns about unfavorable currency impacts, conservative guidance, and risks in 2026. The Q&A section highlights some uncertainties and management's avoidance of specific details, which tempers optimism. The absence of a market cap limits the ability to predict strong movements, leading to a neutral sentiment.
Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
LH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
